Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -4011.86% is 100% below its 5-year average of 8616179.19%, near the low end of its 5-year range (-4011.86%–94783000.00%).
282.93% below its 12-month average of -1047.67%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2025-12-31): -2095.34%.
NET PROFIT MARGIN
-4011.86%
NET PROFIT MARGIN AVG TTM
-1047.67%
NET PROFIT MARGIN AVG 3Y
11847351.17%
NET PROFIT MARGIN AVG 5Y
8616179.19%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-282.93%
CURRENT VS 3Y AVG
-100.03%
CURRENT VS 5Y AVG
-100.05%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 701 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Gelteq Limited Ordinary Shares
Market Cap
$5.14M
Net Profit Margin
-4011.86%
TTM Avg
-1047.67%
3Y Avg
11847351.17%
5Y Avg
8616179.19%
Market Cap
$5.17M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$5.19M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-1794.91%
5Y Avg
-2605.04%
Market Cap
$5.20M
Net Profit Margin
-106.78%
TTM Avg
-43.08%
3Y Avg
-12.30%
5Y Avg
-12.30%
Market Cap
$5.21M
Net Profit Margin
-612568.11%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$5.24M
Net Profit Margin
0.00%
TTM Avg
-61.23%
3Y Avg
-156.55%
5Y Avg
-194.88%
Market Cap
$5.27M
Net Profit Margin
-294.91%
TTM Avg
-320.57%
3Y Avg
-453.36%
5Y Avg
-361.46%
Market Cap
$5.29M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$4.79M
Net Profit Margin
-3985.58%
TTM Avg
-1467.13%
3Y Avg
-2181.72%
5Y Avg
-1717.85%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gelteq Limited Ordinary Shares (GELS) | $5.14M | -4011.86% | -1047.67% | 11847351.17% | 8616179.19% |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.17M | 0.00% | 0.00% | 0.00% | 0.00% |
| Imunon, Inc. (IMNN)vs › | $5.19M | 0.00% | 0.00% | -1794.91% | -2605.04% |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.20M | -106.78% | -43.08% | -12.30% | -12.30% |
| Lunai Bioworks Inc. (LNAI)vs › | $5.21M | -612568.11% | 0.00% | 0.00% | 0.00% |
| Pulmatrix, Inc. (PULM)vs › | $5.24M | 0.00% | -61.23% | -156.55% | -194.88% |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.27M | -294.91% | -320.57% | -453.36% | -361.46% |
| Alzamend Neuro Inc (ALZN)vs › | $5.29M | 0.00% | 0.00% | 0.00% | 0.00% |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.79M | -3985.58% | -1467.13% | -2181.72% | -1717.85% |
| CalciMedica, Inc. (CALC)vs › | $4.72M | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
-3317.7%
Net Profit Margin
-4011.9%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2025-12-31 | -2095.34% |
| 2025-09-30 | -2095.34% |
| 2025-06-30 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-06-30 | 94783000.00% |
| 2023-03-31 | 0.00% |
| 2022-06-30 | -838.21% |
| 2022-03-31 | 0.00% |
| 2021-06-30 | 0.00% |
